The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed.
“The fact that more than 9 months of this year have been focused on the space is unfounded. In fact, I don’t remember one industry in recent history that has so captivated the stock market as much as this,” says the author of today’s article of the biotech space – and biotech penny stocks in particular.
While the surge in interest in pharmaceutical stocks this year has been primarily driven by factors related to the COVID-19 pandemic, the author of today’s article advises that “companies working on pharmaceutical products for unmet needs or other niche markets such as animal health could be worth a closer look.”
“Many scientists believe that this year could be a breakthrough in finding cures for cancer in DNA and investors could get familiar with terms like CRISPR and precision medicine to make the most out of advancements in this space.”
Three biotech companies developing therapies for the treatment of cancer and other diseases – including infectious diseases like COVID-19 – began trading on Friday.
“Make no mistake: These stocks are risky. Nonetheless, each of these companies has a few factors in its favor aside from being popular with retail traders, so if you’re looking for a high-risk and high-reward stock to add to your portfolio, one of these might be worth buying,”